Long-term prognostic value of macrophage migration inhibitory factor in ST-segment elevation myocardial infarction patients with metabolic syndrome after percutaneous coronary intervention.
Long-term prognostic value of macrophage migration inhibitory factor in ST-segment elevation myocardial infarction patients with metabolic syndrome after percutaneous coronary intervention.
复制标题
巨噬细胞迁移抑制因子对ST段抬高型心肌梗死合并代谢综合征患者经皮冠状动脉介入治疗后长期预后的价值
DOI：
10.3389/fcvm.2022.947395
复制
发表时间：
2022
影响因子：
3.6
通讯作者：
Yang, Yi-Ning
中科院分区：
文献类型：
--
作者：
Yu, Xiao-Lin;Zhao, Qian;Liu, Fen;Yuan, Yu-Juan;Fang, Bin-Bin;Zhang, Xue-He;Li, Wen-Ling;Li, Xiao-Mei;Du, Guo-Li;Gao, Xiao-Ming;Yang, Yi-Ning
关键词：
代谢综合征(METS)是心血管疾病的主要危险因素，对ST段抬高心肌梗死(STEMI)患者的预后有负面影响。巨噬细胞移动抑制因子(MIF)是一种多能细胞因子，参与多种心血管疾病和炎症性疾病。在这项前瞻性研究中，我们探讨MIF在STEMI合并METS急诊经皮冠状动脉介入治疗后远期预后中的价值。在入院时测量循环MIF水平，并在4.9(3.9-5.8)年的随访期内监测主要不良心脑血管事件(MACCE)。MACCE92例(22.9%)，METS组(69/255，27.1%)显著高于非MS亚组(23/146，15.8%，P<0.05)。发生MACCE的METS患者入院时MIF水平最高。以入院MIF143 ng/ml为临界值的Kaplan-Meier生存分析显示，MIF水平较高的患者在METS组(P<；0.0001)和非METS组中MIF水平较低的患者发生MACCE的几率更高(P=0.016)。在调整临床变量后，MIF-≥仍有预测能力[HR9.56，95%CI(5.397-16.944)，P<；0.001]，而在非METS组则不是这样。我们的研究结果表明，MET是STEMI患者不良临床结局的关键危险因素，高水平的入院MIF对远期MACCE有预测作用，在STEMI合并METS患者中优于其他传统预测指标。
Metabolic syndrome (MetS) is a major risk factor for cardiovascular disease and negatively affecting the prognosis of patients with ST elevation myocardial infarction (STEMI). Macrophage migration inhibitory factor (MIF) is a multipotent cytokine involved in various cardiovascular and inflammatory diseases. In this prospective study, we investigate the value of MIF in the long-term prognosis of STEMI combined with MetS after emergency PCI. Circulating MIF levels were measured at admission, and major adverse cardiovascular and cerebrovascular events (MACCE) were monitored during the follow-up period of 4.9 (3.9–5.8) years. MACCE occurred in 92 patients (22.9%), which was significantly higher in MetS (69/255, 27.1%) than in the non-MS subgroup (23/146, 15.8%, P < 0.05). Patients with MetS developed MACCE had the highest admission MIF level. Kaplan-Meier survival analysis using the cutoff value of admission MIF (143 ng/ml) showed that patients with a higher MIF level had a greater incidence of MACCE than those with lower MIF levels in both the MetS (P < 0.0001) and non-MetS groups (P = 0.016). After adjustment for clinical variables, the value of MIF ≥ 143 ng/ml still had the predictive power for the MetS group [HR 9.56, 95% CI (5.397–16.944),P < 0.001]; nevertheless, it was not the case in the non-MetS group. Our findings indicated that MetS is a critical risk factor for adverse clinical outcomes in patients with STEMI, and a high admission MIF level has predictive power for the long-term MACCE, which is superior in STEMI patients with MetS and better than other traditional predictors.
登录
查看更多内容
影响因子：
16.2
作者：
Isomaa, B;Almgren, P;Groop, L
通讯作者：
Groop, L
影响因子：
5.3
作者：
Gong, Ping;Luo, Song-Hui;Li, Jian-Jun
通讯作者：
Li, Jian-Jun
影响因子：
6.9
作者：
Reynolds, Kristi;Gu, Dongfeng;Grp, InterASIA Collaborative
通讯作者：
Grp, InterASIA Collaborative
影响因子：
5.8
作者：
Lu, Jieli;Wang, Limin;Ning, Guang
通讯作者：
Ning, Guang
影响因子：
37.8
作者：
Lutsey, Pamela L.;Steffen, Lyn M.;Stevens, June
通讯作者：
Stevens, June